Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NR1H2 | P55055 | 1/20 | 0.41 |
| ▸ | BRD3 | Q15059 | 2/20 | 0.41 |
| ▸ | HPGDS | O60760 | 2/20 | 0.41 |
| ▸ | GPR119 | Q8TDV5 | 3/20 | 0.40 |
| ▸ | GRM5 | P41594 | 2/20 | 0.40 |
| ▸ | GRM1 | Q13255 | 2/20 | 0.40 |
| ▸ | ESR2 | Q92731 | 1/20 | 0.40 |
| ▸ | HDAC1 | Q13547 | 2/20 | 0.39 |
| ▸ | HDAC2 | Q92769 | 2/20 | 0.39 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.38 |
| ▸ | DDB1 | Q16531 | 1/20 | 0.38 |
| ▸ | CRBN | Q96SW2 | 1/20 | 0.38 |
| ▸ | MEN1 | O00255 | 1/20 | 0.38 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.38 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL557260 | 0.88 | ESR2 (0.51) | NR1H2GPR119GRM5ESR2DDB1 | |
| SCHEMBL5161957 | 0.85 | GPR119 (0.43) | NR1H2GPR119GRM5GRM1ESR2 | |
| SCHEMBL30783165 | 0.85 | GPR119 (0.43) | NR1H2GPR119GRM5GRM1ESR2 | |
| SCHEMBL31385916 | 0.84 | HSP90AA1 (0.39) | NR1H2GPR119ESR2HDAC1DDB1 | |
| SCHEMBL556212 | 0.83 | MMP1 (0.37) | NR1H2GPR119ESR2 | |
| SCHEMBL4483494 | 0.82 | RORC (0.47) | NR1H2GPR119GRM5GRM1ESR2 | |
| SCHEMBL11898578 | 0.81 | GPR119 (0.38) | NR1H2GPR119GRM5ESR2DDB1 | |
| SCHEMBL20757938 | 0.80 | KDM4E (0.47) | BRD3GPR119HDAC1HDAC2SMN1; SMN2 | |
| SCHEMBL4029061 | 0.78 | GSK3B (0.43) | BRD3GPR119HDAC1HDAC2SMN1; SMN2 | |
| SCHEMBL5158520 | 0.78 | TACR1 (0.45) | BRD3GPR119HDAC1HDAC2SMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1748984-A1 | PIPERIDINE DERIVATIVES AS NK1 AND NK3 ANTAGONISTS | Pfizer Products Inc. (US) | 2007-02-07 | — | — | EP | disclosed |
| WO-2005110987-A1 | PIPERIDINE DERIVATIVES AS NK1 AND NK3 ANTAGONISTS | PFIZER PRODUCTS INC. (US) | 2005-11-24 | — | — | WO | disclosed |
| US-20050256164-A1 | NK1 and NK3 antagonists | PFIZER INC | 2005-11-17 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050256164-A1 | NK1 and NK3 antagonists | TAC3, TACR1, TACR2 | NR1H2 2428/4885BRD3 1960/4885HPGDS 1785/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.